| Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study P Hillmen, AC Rawstron, K Brock, S Muñoz-Vicente, FJ Yates, R Bishop, ... Journal of clinical oncology 37 (30), 2722-2729, 2019 | 279 | 2019 |
| Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial G Middleton, K Brock, J Savage, R Mant, Y Summers, J Connibear, ... The Lancet Respiratory Medicine 8 (9), 895-904, 2020 | 161 | 2020 |
| Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open … SP Bach, A Gilbert, K Brock, S Korsgen, I Geh, J Hill, T Gill, P Hainsworth, ... The lancet Gastroenterology & hepatology 6 (2), 92-105, 2021 | 152 | 2021 |
| Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial SP Mollan, JL Mitchell, RS Ottridge, M Aguiar, A Yiangou, Z Alimajstorovic, ... JAMA neurology 78 (6), 678-686, 2021 | 121 | 2021 |
| How to design a dose-finding study using the continual reassessment method GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ... BMC medical research methodology 19, 1-15, 2019 | 99 | 2019 |
| Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension V Vijay, SP Mollan, JL Mitchell, E Bilton, Z Alimajstorovic, KA Markey, ... JAMA ophthalmology 138 (12), 1264-1271, 2020 | 76 | 2020 |
| Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, ... Journal of Clinical Oncology 37 (7), 580-588, 2019 | 69 | 2019 |
| The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial JL Mitchell, HS Lyons, JK Walker, A Yiangou, O Grech, Z Alimajstorovic, ... Brain 146 (5), 1821-1830, 2023 | 67 | 2023 |
| Sustained release of decorin to the surface of the eye enables scarless corneal regeneration LJ Hill, RJA Moakes, C Vareechon, G Butt, A Ng, K Brock, G Chouhan, ... NPJ Regenerative medicine 3 (1), 23, 2018 | 60 | 2018 |
| Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension SP Mollan, BR Wakerley, Z Alimajstorovic, J Mitchell, R Ottridge, ... The journal of headache and pain 22, 1-9, 2021 | 49 | 2021 |
| Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication … P Hillmen, T Munir, A Rawstron, K Brock, SM Vicente, F Yates, R Bishop, ... Blood 130, 428, 2017 | 47 | 2017 |
| Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): results of the PePS2 trial G Middleton, K Brock, Y Summers, J Connibear, R Shah, C Ottensmeier, ... Annals of Oncology 29, viii497, 2018 | 40 | 2018 |
| Association of amount of weight lost after bariatric surgery with intracranial pressure in women with idiopathic intracranial hypertension SP Mollan, JL Mitchell, A Yiangou, RS Ottridge, Z Alimajstorovic, ... Neurology 99 (11), e1090-e1099, 2022 | 39 | 2022 |
| Do we need to adjust for interim analyses in a Bayesian adaptive trial design? EG Ryan, K Brock, S Gates, D Slade BMC Medical Research Methodology 20, 1-9, 2020 | 34 | 2020 |
| Implementing the EffTox dose-finding design in the Matchpoint trial K Brock, L Billingham, M Copland, S Siddique, M Sirovica, C Yap BMC medical research methodology 17, 1-15, 2017 | 33 | 2017 |
| Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the bloodwise TAP clarity study P Hillmen, A Rawstron, K Brock, SM Vicente, F Yates, R Bishop, ... Blood 132, 182, 2018 | 32 | 2018 |
| Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT … M Copland, D Slade, G McIlroy, G Horne, JL Byrne, K Rothwell, K Brock, ... The Lancet Haematology 9 (2), e121-e132, 2022 | 28 | 2022 |
| Violet-blue light arrays at 405 nanometers exert enhanced antimicrobial activity for photodisinfection of monomicrobial nosocomial biofilms FD Halstead, MA Hadis, N Marley, K Brock, MR Milward, PR Cooper, ... Applied and environmental microbiology 85 (21), e01346-19, 2019 | 21 | 2019 |
| Continued long term responses to ibrutinib+ venetoclax treatment for relapsed/refractory CLL in the blood cancer UK TAP clarity trial P Hillmen, RH Boucher, N Webster, S Dalal, K Brock, F Yates, ... Blood 136, 17-18, 2020 | 19 | 2020 |
| FLAG-IDA and ponatinib in patients with blast phase chronic myeloid leukaemia: results from the phase I/II UK trials acceleration programme matchpoint trial M Copland, D Slade, J Byrne, K Brock, H De Lavallade, C Craddock, ... Blood 134, 497, 2019 | 19 | 2019 |
Peter HillmenUniversity of LeedsVerified email at leeds.ac.uk
